why choose us

300×250 Ad Slot

Research Article: Intravitreal Ziv-Aflibercept versus Bevacizumab for Naïve Central Retinal Vein Occlusion with Macular Edema: An Interim Analysis of a Randomized Non-Inferiority Trial

Date Published: 2023-09-18

Introduction:
Macular edema (ME) is the most common complication of central retinal vein occlusion (CRVO), which can lead to visual deterioration. Vascular endothelial growth factor (VEGF) plays a key role in the pathogenesis of ME secondary to CRVO. , Off-label anti-VEGF drug, bevacizumab, and approved anti-VEGF agents from the Food and Drug Administration, including ranibizumab and aflibercept, are used worldwide. Among anti-VEGF agents, aflibercept is considered the first choice of treatment in terms of visual improvement,…

Read more

300×250 Ad Slot